We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





BioMérieux’s New CE-Marked Mass Spectrometry System Makes Lab Life Easier During COVID-19 Pandemic

By LabMedica International staff writers
Posted on 10 May 2021
Print article
Image: VITEK MS PRIME (Photo courtesy of BioMérieux)
Image: VITEK MS PRIME (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has announced the CE-marking of VITEK MS PRIME, the next generation of the VITEK MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes that aims to make lab life easier during the COVID-19 pandemic.

Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy. Including time-saving innovations to deliver faster identification results, VITEK MS PRIME is a compact benchtop system designed to increase laboratory productivity for greater impact to patient care.

VITEK MS PRIME is a Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer that analyzes material from microbial cultures to provide microorganism identification. Samples are submitted to multiple laser shots inside VITEK MS PRIME. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization). Electric fields then guide the ions into a vacuum tube which separates them according to their weight, with the smaller molecules rising up the column faster than the larger molecules. This “time of flight” creates a series of peaks, which correspond with the different molecules contained in the organism from the sample. All of these peaks create spectra unique to that microorganism. By comparing the spectra to a vast comprehensive library owned by bioMérieux, the precise microorganism can be identified quickly and easily. VITEK MS PRIME has been designed to incorporate additional benefits to further enhance the use of the MALDI-TOF technology.

With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority. Antimicrobial Stewardship (AMS), a key part of the arsenal to fight resistance, starts with diagnostics. VITEK MS PRIME positively impacts stewardship programs by providing even faster, highly accurate pathogen identification making excellent use of the large database of clinically relevant species to support earlier, targeted therapy.

“We had extensive input directly from labs as we developed VITEK MS PRIME,” said François Lacoste, Executive Vice President R&D. “The system incorporates numerous innovative features to make lab life easier, including improved automation and serviceability, with a robust database that is consistently expanding with new emerging pathogens and clinically relevant species. It integrates seamlessly with VITEK 2 for antimicrobial susceptibility testing and MYLA middleware for data integration and insights.”

“We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, “VITEK MS PRIME is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous ‘load and go’ allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance.”

Related Links:
BioMérieux

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.